What patient profiles or clinical contexts would justify the initiation of elinzanetant (Lynkuet) for postmenopausal vasomotor symptoms, considering its mechanism and current evidence base?

Elinzanetant is indicated for the treatment of moderate to severe VMS due to menopause in adult women. The VMS includes hot flashes and night sweats. This drug acts as a neurokinin 1 and neurokinin 3 receptor antagonist, thus modulating thermoregulatory pathways. The indications were supported by tw...